Voltage-Gated Sodium Channels as Therapeutic Targets

Therapeutic Targets: Modulation, Inhibition, and Activation

Volumn , Issue , 2012, Pages 63-122

  Wingerd, Joshua S ^a   Vetter, Irina ^a   Lewis, Richard J ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Novel, high throughput electrophysiology, for novel drug leads; Protein protein modulation of Nav channels; Sodium (Na+) channels, gated pores conducting Na+ into cell types; Voltage gated sodium channels, as therapeutic targets; Voltage gated sodium channels, therapeutic targets in diseases

Indexed keywords

EID: 84887252097     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118185537.ch3     Document Type: Chapter

References (367)

1. Jan LY, Jan YN. Tracing the roots of ion channels. Cell 69:715-718 (1992).
2. Hille B. Ion Channels of Excitable Membranes, Sinauer, Sunderland, MA, 2001.
3. Hille B. The Sharpey-Schafer Lecture. Ionic channels: Evolutionary origins and modern roles. Q J Exp Physiol 74:785-804 (1989).
4. Strong M, Chandy KG, Gutman GA. Molecular evolution of voltage-sensitive ion channel genes: On the origins of electrical excitability. Mol Biol Evol 10:221-242 (1993).
5. Catterall WA, Goldin AL, Waxman SG. International Union of Pharmacology. XLVII. Nomenclature and structure-function relationships of voltage-gated sodium channels. Pharmacol Rev. 57:397-409 (2005).
6. Roy M, Narahashi T. Differential properties of tetrodotoxin-sensitive and tetrodotoxinresistant sodium channels in rat dorsal root ganglion neurons. J Neurosci 12:2104-2111 (1992).
7. Hains BC et al. Upregulation of sodium channel Nav1.3 and functional involvement in neuronal hyperexcitability associated with central neuropathic pain after spinal cord injury. J Neurosci 23:8881-8892 (2003).
8. Maingret F et al. Inflammatory mediators increase Nav1. 9 current and excitability in nociceptors through a coincident detectionmechanism.JGenPhysiol 131:211-225 (2008).
9. Shah BS, Stevens EB, Pinnock RD, Dixon AK, Lee, K. Developmental expression of the novel voltage-gated sodium channel auxiliary subunit beta3, in rat CNS. J Physiol 534:763-776 (2001).
10. Thimmapaya R et al. Distribution and functional characterization of human Nav1.3 splice variants. Eur J Neurosci 22:1-9 (2005).
11. Plummer NW, Meisler MH. Evolution and diversity of mammalian sodium channel genes. Genomics 57:323-331 (1999).
12. Meisler MH, Kearney J, Escayg A, Macdonald BT, Sprunger LK. Sodium channels and neurological disease: Insights from Scn8a mutations in the mouse. Neurosci 7:136-145 (2001).
13. CatterallWA. From ionic currents to molecular mechanisms: The structure and function of voltage-gated sodium channels. Neuron 26:13-25 (2000).
14. Yu FH et al. Sodium channel beta4, a new disulfide-linked auxiliary subunit with similarity to beta2. J Neurosci 23:7577-7585 (2003).
15. Messner DJ, Catterall WA. The sodium channel from rat brain. Separation and characterization of subunits. J Biol Chem 260:10597-10604 (1985).
16. Vijayaragavan K, Powell AJ, Kinghorn IJ, Chahine M. Role of auxiliary beta1-, beta2-, and beta3-subunits and their interaction with Na(v)1.8 voltage-gated sodium channel. Biochem Biophys Res Commun 319:531-540 (2004).
17. Brackenbury WJ, Djamgoz MB, Isom LL. An emerging role for voltage-gated Na+ channels in cellular migration: Regulation of central nervous system development and potentiation of invasive cancers. Neuroscientist 14:571-583 (2008).
18. Qin N et al. Molecular cloning and functional expression of the human sodium channel beta1B subunit, a novel splicing variant of the beta1 subunit. Eur J Biochem 270:4762- 4770 (2003).
19. Catterall WA. Structure and modulation of Na+ and Ca2+ channels. Ann NY Acad Sci 707:1-19 (1993).
20. Catterall WA. A 3D view of sodium channels. Nature 409:988-989, 991 (2001).
21. Vora T, Corry B, Chung SH. A model of sodium channels. Biochim Biophys Acta 1668:106-116 (2005).
22. Payandeh J, Scheuer T, Zheng N, Catterall WA. The crystal structure of a voltage-gated sodium channel. Nature 475(7356):353-358 (2011).
23. Lipkind GM, Fozzard HA. A structural model of the tetrodotoxin and saxitoxin binding site of the Na+ channel. Biophys J 66:1-13 (1994).
24. Heinemann SH, Terlau H, Imoto K. Molecular basis for pharmacological differences between brain and cardiac sodium channels. Pflugers Arch 422:90-92 (1992).
25. Satin J et al. A mutant of TTX-resistant cardiac sodium channels with TTX-sensitive properties. Science 256:1202-1205 (1992).
26. Noda M, Suzuki H, Numa S, Stuhmer W. A single point mutation confers tetrodotoxin and saxitoxin insensitivity on the sodium channel II. FEBS Lett 259:213-216 (1989).
27. Terlau H et al. Mapping the site of block by tetrodotoxin and saxitoxin of sodium channel II. FEBS Lett 293:93-96 (1991).
28. Heinemann SH, Terlau H, Stuhmer W, Imoto K, Numa S. Calcium channel characteristics conferred on the sodium channel by single mutations. Nature 356:441-443 (1992).
29. Favre I, Moczydlowski E, Schild L. On the structural basis for ionic selectivity among Na+, K+, and Ca2+ in the voltage-gated sodium channel. Biophys J 71:3110-3125 (1996).
30. Chiamvimonvat N, Perez-Garcia MT, Tomaselli GF, Marban E. Control of ion flux and selectivity by negatively charged residues in the outer mouth of rat sodium channels. J Physiol 491(Pt 1):51-59 (1996).
31. Fozzard HA, Lipkind GM. The tetrodotoxin binding site is within the outer vestibule of the sodium channel. Mar Drugs 8:219-234 (2010).
32. Lipkind GM, Fozzard HA. Molecular model of anticonvulsant drug binding to the voltage-gated sodium channel inner pore. Mol Pharmacol 78(4):631-638 (2010).
33. Ulbricht W. Sodium channel inactivation: Molecular determinants and modulation. Physiol Rev 85:1271-1301 (2005).
34. Stuhmer Wet al. Structural parts involved in activation and inactivation of the sodium channel. Nature 339:597-603 (1989).
35. Vassilev P, Scheuer T, Catterall W. Inhibition of inactivation of single sodium channels by a site-directed antibody. Proc Natl Acad Sci USA 86:8147-8151 (1989).
36. West JW et al. A cluster of hydrophobic amino acid residues required for fast Na(+)-channel inactivation. Proc Natl Acad Sci USA 89:10910-10914 (1992).
37. Eaholtz G, Zagotta WN, Catterall WA. Kinetic analysis of block of open sodium channels by a peptide containing the isoleucine, phenylalanine, and methionine (IFM) motif from the inactivation gate. J Gen Physiol 111:75-82 (1998).
38. Rohl CA et al. Solution structure of the sodium channel inactivation gate. Biochemistry 38:855-861 (1998).
39. Motoike HK et al. The Na+ channel inactivation gate is a molecular complex: A novel role of the COOH-terminal domain. J Gen Physiol 123:155-165 (2004).
40. Vedantham V, Cannon SC. Slow inactivation does not affect movement of the fast inactivation gate in voltage-gated Na+ channels. J Gen Physiol 111:83-93 (1998).
41. Featherstone DE, Richmond JE, Ruben PC. Interaction between fast and slow inactivation in Skm1 sodium channels. Biophys J 71:3098-3109 (1996).
42. Liu Y, Jurman ME, Yellen G. Dynamic rearrangement of the outer mouth of a K+ channel during gating. Neuron 16:859-867 (1996).
43. Yellen G, Sodickson D, Chen TY, Jurman ME. An engineered cysteine in the external mouth of a K+ channel allows inactivation to be modulated by metal binding. Biophys J 66:1068-1075 (1994).
44. Hoshi T, Zagotta WN, Aldrich RW. Two types of inactivation in Shaker K+ channels: Effects of alterations in the carboxy-terminal region. Neuron 7:547-556 (1991).
45. Tikhonov DB, Zhorov BS. Sodium channels: Ionic model of slow inactivation and statedependent drug binding. Biophys J 93:1557-1570 (2007).
46. Ruff RL, Simoncini L, Stuhmer W. Slow sodium channel inactivation in mammalian muscle: A possible role in regulating excitability. Muscle Nerve 11:502-510 (1988).
47. Hayward LJ, Sandoval GM, Cannon SC. Defective slow inactivation of sodium channels contributes to familial periodic paralysis. Neurology 52:1447-1453 (1999).
48. Alekov AK, Rahman MM, Mitrovic N, Lehmann-Horn F, Lerche H. Enhanced inactivation and acceleration of activation of the sodium channel associated with epilepsy in man. Eur J Neurosci 13:2171-2176 (2001).
49. Veldkamp MW et al. Two distinct congenital arrhythmias evoked by a multidysfunctional Na(+) channel. Circ Res 86:E91-E97 (2000).
50. Wang DW, Viswanathan PC, Balser JR, George AL, Jr, Benson DW. Clinical, genetic, and biophysical characterization of SCN5A mutations associated with atrioventricular conduction block. Circulation 105:341-346 (2002).
51. Groenewegen WA et al. A novel LQT3 mutation implicates the human cardiac sodium channel domain IVS6 in inactivation kinetics. Cardiovasc Res 57:1072-1078 (2003).
52. Richmond JE, Featherstone DE, Hartmann HA, Ruben PC. Slow inactivation in human cardiac sodium channels. Biophys J 74:2945-2952 (1998).
53. Wang SY, Wang GK. A mutation in segment I-S6 alters slow inactivation of sodium channels. Biophys J 72:1633-1640 (1997).
54. Vilin YY, Makita N, George AL, Jr, Ruben PC. Structural determinants of slow inactivation in human cardiac and skeletal muscle sodium channels. Biophys J 77:1384-1393 (1999).
55. Xiong W. et al. A conserved ring of charge in mammalian Na+ channels: A molecular regulator of the outer pore conformation during slow inactivation. J Physiol 576:739- 754 (2006).
56. Noda M. et al. Primary structure of electrophorus electricus sodium channel deduced from cDNA sequence. Nature 312:121-127 (1984).
57. Armstrong CM. Sodium channels and gating currents. Physiol Rev 61:644-683 (1981).
58. Catterall W. Voltage-dependent gating of sodium channels: Correlating structure and function. Trends Neurosci 9:7-10 (1986).
59. DeCaen PG, Yarov-Yarovoy V, Sharp EM, Scheuer T, Catterall WA. Sequential formation of ion pairs during activation of a sodium channel voltage sensor. Proc Natl Acad Sci USA 106:22498-22503 (2009).
60. DeCaen PG, Yarov-Yarovoy V, Zhao Y, Scheuer T, Catterall WA. Disulfide locking a sodium channel voltage sensor reveals ion pair formation during activation. Proc Natl Acad Sci USA 105:15142-15147 (2008).
61. Bezanilla F. The voltage sensor in voltage-dependent ion channels. Physiol Rev 80:555- 592 (2000).
62. Shao D, Okuse K, Djamgoz MB. Protein-protein interactions involving voltage-gated sodium channels: Post-translational regulation, intracellular trafficking and functional expression. Int J Biochem Cell Biol 41:1471-1481 (2009).
63. Okuse K et al. Annexin II light chain regulates sensory neuron-specific sodium channel expression. Nature 417:653-656 (2002).
64. SharkeyLM et al. The ataxia3 mutation in the N-terminal cytoplasmic domain of sodium channel Nav1.6 disrupts intracellular trafficking. J Neurosci 29:2733-2741 (2009).
65. Lee A, Goldin AL. Role of the terminal domains in sodium channel localization. Channels (Austin) 3:171-180 (2009).
66. Mantegazza M, Yu FH, Catterall WA, Scheuer T. Role of the C-terminal domain in inactivation of brain and cardiac sodium channels. Proc Natl Acad Sci USA 98:15348-15353 (2001).
67. Nguyen HM, Goldin AL. Sodium channel carboxyl-terminal residue regulates fast inactivation. J. Biol Chem 285:9077-9089 (2010).
68. Liang H et al. Unified mechanisms of Ca2+ regulation across the Ca2+ channel family. Neuron 39:951-960 (2003).
69. Herzog RI, Liu C, Waxman SG, Cummins TR. Calmodulin binds to the C terminus of sodium channels Nav1.4 and Nav1.6 and differentially modulates their functional properties. J Neurosci 23:8261-8270 (2003).
70. Young KA, Caldwell JH. Modulation of skeletal and cardiac voltage-gated sodium channels by calmodulin. J Physiol 565:349-370 (2005).
71. Miloushev VZ et al. Solution structure of the NaV1.2 C-terminal EF-hand domain. J Biol Chem 284:6446-6454 (2009).
72. Lemaillet G, Walker B, Lambert S. Identification of a conserved ankyrin-binding motif in the family of sodium channel alpha subunits. J Biol Chem 278:27333-27339 (2003).
73. Garrido JJ et al. A targeting motif involved in sodium channel clustering at the axonal initial segment. Science 300:2091-2094 (2003).
74. Mohler PJ, Bennett V. Ankyrin-based cardiac arrhythmias: A new class of channelopathies due to loss of cellular targeting. Curr Opin Cardiol 20:189-193 (2005).
75. Cantrell AR, Catterall WA. Neuromodulation of Na+ channels: An unexpected form of cellular plasticity. Nat Rev Neurosci 2:397-407 (2001).
76. Murphy BJ, Rossie S, De Jongh KS, CatterallWA. Identification of the sites of selective phosphorylation and dephosphorylation of the rat brain Na+ channel alpha subunit by cAMP-dependent protein kinase and phosphoprotein phosphatases. J Biol Chem 268:27355-27362 (1993).
77. West JW, Numann R, Murphy BJ, Scheuer T, Catterall WA. A phosphorylation site in the Na+ channel required for modulation by protein kinase C. Science 254:866-868 (1991).
78. Louvet-Vallee S. ERM proteins: From cellular architecture to cell signaling. Biol Cell 92:305-316 (2000).
79. Malik-Hall M, Poon WY, Baker MD, Wood JN, Okuse K. Sensory neuron proteins interact with the intracellular domains of sodium channel NaV1.8. Brain Res Mol Brain Res 110:298-304 (2003).
80. Gee SH et al. Interaction of muscle and brain sodium channels with multiple members of the syntrophin family of dystrophin-associated proteins. J Neurosci 18:128-137 (1998).
81. Schultz J et al. Specific interactions between the syntrophin PDZ domain and voltagegated sodium channels. Nat Struct Biol 5:19-24 (1998).
82. Gavillet B et al. Cardiac sodium channel Nav1. 5 is regulated by a multiprotein complex composed of syntrophins and dystrophin. Circ Res 99, 407-414 (2006).
83. Brackenbury WJ, Isom LL. Voltage-gated Na+ channels: Potential for beta subunits as therapeutic targets. Expert Opin Ther Targets 12:1191-11203 (2008).
84. Patino GA, Isom LL. Electrophysiology and beyond: Multiple roles of Na+ channel [beta] subunits in development and disease. Neurosci Lett 486:53-59.
85. Morgan, K et al. beta3: An additional auxiliary subunit of the voltage-sensitive sodium channel that modulates channel gating with distinct kinetics. Proc Natl Acad Sci USA 97:2308-2313 (2000).
86. Isom LL et al. Structure and function of the [beta]2 subunit of brain sodium channels, a transmembrane glycoprotein with a CAM motif. Cell 83:433-442 (1995).
87. Isom L et al. Primary structure and functional expression of the beta 1 subunit of the rat brain sodium channel. Science 256:839-842 (1992).
88. Kim DY, Ingano LA, Carey BW, Pettingell WH, Kovacs DM. Presenilin/gammasecretase- mediated cleavage of the voltage-gated sodium channel beta2-subunit regulates cell adhesion and migration. J Biol Chem 280:23251-23261 (2005).
89. Davis TH, Chen C, Isom LL. Sodium channel beta1 subunits promote neurite outgrowth in cerebellar granule neurons. J Biol Chem 279:51424-51432 (2004).
90. Chioni AM, Brackenbury WJ, Calhoun JD, Isom LL, Djamgoz MB. A novel adhesion molecule in human breast cancer cells: Voltage-gated Na+ channel beta1 subunit. Int J Biochem Cell Biol 41:1216-1227 (2009).
91. WatanabeHet al.Sodiumchannel beta1 subunit mutations associated with Brugada syndrome and cardiac conduction disease in humans. J. Clin. Investig. 118:2260-2268 (2008).
92. Scheffer IE et al. Temporal lobe epilepsy and GEFS+ phenotypes associated with SCN1B mutations. Brain 130:100-109 (2007).
93. Wallace R et al. Febrile seizures and generalized epilepsy associated with a mutation in the Na+-channel beta1 subunit gene SCN1B. Nat Genet 19:366-370 (1998).
94. Dib-Hajj SD, Black JA, Waxman SG. Voltage-gated sodium channels: Therapeutic targets for pain. Pain Med 10:1260-1269 (2009).
95. Waxman SG. Mechanisms of disease: Sodium channels and neuroprotection in multiple sclerosis-current status. Nat Clin Pract Neurol 4:159-169 (2008).
96. Tfelt-Hansen J,Winkel BG, Grunnet M, Jespersen T. Inherited cardiac diseases caused by mutations in the Nav1.5 sodiumchannel. J Cardiovasc Electrophysiol 21:107-115 (2010).
97. Leterrier C, Brachet A, Fache MP, Dargent B. Voltage-gated sodium channel organization in neurons: Protein interactions and trafficking pathways. Neurosci Lett 486(2):92- 100 (2010).
98. Fraser SP et al. Voltage-gated sodium channel expression and potentiation of human breast cancer metastasis. Clin Cancer Res 11:5381-5389 (2005).
99. Black JA et al. Spinal sensory neurons express multiple sodium channel alpha-subunit mRNAs. Brain Res Mol Brain Res 43:117-131 (1996).
100. Renganathan M, Dib-Hajj S, Waxman SG Na(v)1.5 underlies the "third TTX-R sodium current" in rat small DRG neurons. Brain Res Mol Brain Res 106:70-82 (2002).
101. Waxman SG, Kocsis JD, Black JA. Type III sodium channel mRNA is expressed in embryonic but not adult spinal sensory neurons, and is reexpressed following axotomy. J Neurophysiol 72:466-470 (1994).
102. Kim CH, Oh, Y, Chung JM, Chung K. The changes in expression of three subtypes of TTX sensitive sodium channels in sensory neurons after spinal nerve ligation. Brain Res Mol Brain Res 95:153-161 (2001).
103. Cummins TR et al. Nav1.3 sodium channels: Rapid repriming and slow closed-state inactivation display quantitative differences after expression in a mammalian cell line and in spinal sensory neurons. J Neurosci 21, 5952-5961 (2001).
104. Dib-Hajj S, Black JA, Felts P, Waxman SG. Down-regulation of transcripts for Na channel alpha-SNS in spinal sensory neurons following axotomy. Proc Natl Acad Sci USA 93:14950-14954 (1996).
105. Hains BC, Saab CY, Klein JP, Craner MJ, Waxman SG. Altered sodium channel expression in second-order spinal sensory neurons contributes to pain after peripheral nerve injury. J Neurosci 24:4832-4839 (2004).
106. Hains BC, Saab CY, Waxman SG. Changes in electrophysiological properties and sodium channel Nav1.3 expression in thalamic neurons after spinal cord injury. Brain 128, 2359-2371 (2005).
107. Nassar MA. et al. Nerve injury induces robust allodynia and ectopic discharges in Nav1.3 null mutant mice. Mol Pain 2:33 (2006).
108. Lindia JA, Kohler MG, Martin WJ, Abbadie, C. Relationship between sodium channel NaV1.3 expression and neuropathic pain behavior in rats. Pain 117:145-153 (2005).
109. Dib-Hajj SD et al. Voltage-gated sodium channels in pain states: Role in pathophysiology and targets for treatment. Brain Res Rev 60:65-83 (2009).
110. Toledo-Aral JJ et al. Identification of PN1, a predominant voltage-dependent sodium channel expressed principally in peripheral neurons. Proc Natl Acad Sci USA 94:1527- 1532 (1997).
111. Felts PA, Yokoyama S, Dib-Hajj S, Black JA, Waxman SG. Sodium channel alphasubunit mRNAs I, II, III, NaG, Na6 and hNE (PN1): Different expression patterns in developing rat nervous system. Brain Res Mol Brain Res 45:71-82 (1997).
112. Klugbauer N, Lacinova L, Flockerzi V, Hofmann F. Structure and functional expression of a new member of the tetrodotoxin-sensitive voltage-activated sodium channel family from human neuroendocrine cells. EMBO J 14:1084-1090 (1995).
113. Sangameswaran L et al. A novel tetrodotoxin-sensitive, voltage-gated sodium channel expressed in rat and human dorsal root ganglia. J Biol Chem 272:14805-14809 (1997).
114. Cummins TR, Howe JR, Waxman SG. Slow closed-state inactivation: A novel mechanism underlying ramp currents in cells expressing the hNE/PN1 sodium channel. J Neurosci 18:9607-9619 (1998).
115. Cummins TR, Sheets PL, Waxman SG. The roles of sodium channels in nociception: Implications for mechanisms of pain. Pain 131:243-257 (2007).
116. Herzog RI, Cummins TR, Ghassemi F, Dib-Hajj SD, Waxman SG. Distinct repriming and closed-state inactivation kinetics of Nav1.6 and Nav1.7 sodium channels in mouse spinal sensory neurons. J Physiol 551:741-750 (2003).
117. Fertleman CR et al. SCN9A mutations in paroxysmal extreme pain disorder: Allelic variants underlie distinct channel defects and phenotypes. Neuron 52:767-774 (2006).
118. Waxman SG, Dib-Hajj SD. Erythromelalgia: A hereditary pain syndrome enters the molecular era. Ann Neurol 57:785-788 (2005).
119. Cox JJ et al. An SCN9A channelopathy causes congenital inability to experience pain. Nature 444:894-898 (2006).
120. Goldberg YP et al. Loss-of-function mutations in the Nav1.7 gene underlie congenital indifference to pain in multiple human populations. Clin Genet 71:311-319 (2007).
121. Fischer TZ, Waxman SG. Familial pain syndromes from mutations of the NaV1.7 sodium channel. Ann NY Acad Sci 1184:196-207 (2010).
122. Black JA, Liu S, Tanaka M, Cummins TR, Waxman SG. Changes in the expression of tetrodotoxin-sensitive sodium channels within dorsal root ganglia neurons in inflammatory pain. Pain 108:237-247 (2004).
123. Toledo-Aral JJ, Brehm P, Halegoua S, Mandel G. A single pulse of nerve growth factor triggers long-term neuronal excitability through sodium channel gene induction. Neuron 14:607-611 (1995).
124. Renganathan M, Cummins TR, Waxman SG. Contribution of Na(v)1.8 sodium channels to action potential electrogenesis in DRG neurons. J Neurophysiol 86:629-640 (2001).
125. Blair NT, Bean BP. Roles of tetrodotoxin (TTX)-sensitive Na+ current, TTX-resistant Na+ current, and Ca2+ current in the action potentials of nociceptive sensory neurons. J Neurosci 22:10277-10290 (2002).
126. Sangameswaran L et al. Structure and function of a novel voltage-gated, tetrodotoxinresistant sodium channel specific to sensory neurons. J Biol Chem 271:5953-5956 (1996).
127. Akopian AN, Sivilotti L, Wood JN. A tetrodotoxin-resistant voltage-gated sodium channel expressed by sensory neurons. Nature 379:257-262 (1996).
128. Rizzo MA, Kocsis JD, Waxman SG. Slow sodium conductances of dorsal root ganglion neurons: intraneuronal homogeneity and interneuronal heterogeneity. J Neurophysiol 72:2796-2815 (1994).
129. Roy ML, Narahashi T. Differential properties of tetrodotoxin-sensitive and tetrodotoxinresistant sodium channels in rat dorsal root ganglion neurons. J Neurosci 12:2104-2111 (1992).
130. Choi JS, Dib-Hajj SD, Waxman SG. Differential slow inactivation and use-dependent inhibition of Nav1.8 channels contribute to distinct firing properties in IB4+ and IB4- DRG neurons. J Neurophysiol 97:1258-1265 (2007).
131. RushAM et al. A single sodium channel mutation produces hyper- or hypoexcitability in different types of neurons. Proc Natl Acad Sci USA 103:8245-8250 (2006).
132. Gold MS, Zhang L, Wrigley DL, Traub RJ. Prostaglandin E(2) modulates TTX-R I(Na) in rat colonic sensory neurons. J Neurophysiol 88:1512-1522 (2002).
133. Gold MS, Levine JD. DAMGO inhibits prostaglandin E2-induced potentiation of a TTX-resistant Na+ current in rat sensory neurons in vitro. Neurosci Lett 212:83-86 (1996).
134. Akopian AN. et al. The tetrodotoxin-resistant sodium channel SNS has a specialized function in pain pathways. Nat Neurosci 2:541-548 (1999).
135. Hillsley K et al. Dissecting the role of sodium currents in visceral sensory neurons in a model of chronic hyperexcitability using Nav1.8 and Nav1.9 null mice. J Physiol 576:257-267 (2006).
136. Laird JM, Souslova V, Wood JN, Cervero F. Deficits in visceral pain and referred hyperalgesia in Nav1.8 (SNS/PN3)-null mice. J Neurosci 22:8352-8356 (2002).
137. Zhang YH, Vasko MR, Nicol GD. Ceramide, a putative second messenger for nerve growth factor, modulates the TTX-resistant Na(+) current and delayed rectifier K(+) current in rat sensory neurons. J Physiol 544:385-402 (2002).
138. Nassar MA, Levato A, Stirling LC, Wood JN. Neuropathic pain develops normally in mice lacking both Na(v)1.7 and Na(v)1.8. Mol Pain 1:24 (2005).
139. Zimmermann K et al. Sensory neuron sodium channel Nav1.8 is essential for pain at low temperatures. Nature 447:855-858 (2007).
140. Abrahamsen B et al. The cell and molecular basis of mechanical, cold, and inflammatory pain. Science 321:702-705 (2008).
141. Dib-Hajj SD, Tyrrell, L, Black JA,Waxman SG. NaN, a novel voltage-gated Na channel, is expressed preferentially in peripheral sensory neurons and down-regulated after axotomy. Proc Natl Acad Sci USA 95:8963-8968 (1998).
142. Cummins TR et al. A novel persistent tetrodotoxin-resistant sodium current in SNS-null and wild-type small primary sensory neurons. J Neurosci 19:RC43 (1999).
143. Priest BT et al. Contribution of the tetrodotoxin-resistant voltage-gated sodium channel NaV1.9 to sensory transmission and nociceptive behavior. Proc Natl Acad Sci USA 102:9382-9387 (2005).
144. Leo S, D'Hooge, R, Meert, T. Exploring the role of nociceptor-specific sodium channels in pain transmission using Nav1.8 and Nav1.9 knockout mice. Behav Brain Res 208:149-157 (2009).
145. Platt D, Griggs R. Skeletal muscle channelopathies: New insights into the periodic paralyses and nondystrophic myotonias. Curr Opin Neurol 22:524-531 (2009).
146. Camerino DC et al. Therapeutic approaches to ion channel diseases. Advances in Genetics 64:81-145 (2008).
147. Davies NP, Hanna MG. Neurological channelopathies: Diagnosis and therapy in the new millennium. Ann Med 31:406-420 (1999).
148. Heatwole CR, Moxley RT III, The nondystrophic myotonias. Neurotherapeutics 4:238-251 (2007).
149. Wang Q et al. Cardiac sodium channel mutations in patients with long QT syndrome, an inherited cardiac arrhythmia. Hum Mol Genet 4:1603-1607 (1995).
150. Ruan Y, Liu N, Priori SG. Sodium channel mutations and arrhythmias. Nat Rev Cardiol 6:337-348 (2009).
151. Lei M, Huang CL, Zhang Y. Genetic Na+ channelopathies and sinus node dysfunction. Prog Biophys Mol Biol 98:171-178 (2008).
152. Chen Q et al. Genetic basis and molecular mechanism for idiopathic ventricular fibrillation. Nature 392:293-296 (1998).
153. Priori SG, Napolitano C, Vicentini A. Inherited arrhythmia syndromes: Applying the molecular biology and genetic to the clinical management. J Interv Card Electrophysiol 9:93-101 (2003).
154. Milne JR et al. Class 1 antiarrhythmic drugs-characteristic electrocardiograph differences when assessed by atrial and ventricular pacing. Eur Heart J 5:99-107 (1984).
155. Rang HP, Dale MM, Ritter JM, Moore PK. Pharmacology, 5th ed., Churchill Livingstone, Edinburgh, 2003.
156. SinghBN. Current antiarrhythmic drugs. J Cardiovasc Electrophysiol 10:283-301 (1999).
157. Lossin C. A catalog of SCN1A variants. Brain Dev 31:114-130 (2009).
158. Harkin LA et al. The spectrum of SCN1A-related infantile epileptic encephalopathies. Brain 130:843-852 (2007).
159. Holland KD et al. Mutation of sodium channel SCN3A in a patient with cryptogenic pediatric partial epilepsy. Neurosci Lett 433:65-70 (2008).
160. Estacion M, Gasser A, Dib-Hajj SD,Waxman SG. A sodium channel mutation linked to epilepsy increases ramp and persistent current of Nav1.3 and induces hyperexcitability in hippocampal neurons. Exp. Neuro. 224:362-368 (2010).
161. Blumenfeld H et al. Role of hippocampal sodium channel Nav1.6 in kindling epileptogenesis. Epilepsia 50:44-55 (2009).
162. Meisler MH, O'Brien JE, Sharkey LM. Sodium channel gene family: Epilepsy mutations, gene interactions and modifier effects. J Physiol 588:1841-1848 (2010).
163. Aman TK et al. Regulation of persistent Na current by interactions between {beta} subunits of voltage-gated Na channels. J Neurosci 29:2027-2042 (2009).
164. Van Gassen KLI et al. Hippocampal Navb3 expression in patients with temporal lobe epilepsy. Epilepsia 50:957-962 (2009).
165. Ragsdale DS. How do mutant Nav1.1 sodium channels cause epilepsy? Brain Res Rev 58:149-159 (2008).
166. Catterall WA, Kalume F, Oakley JC. NaV1.1 channels and epilepsy. J Physiol 588:1849-1859 (2010).
167. Guo F et al. Voltage-gated sodium channel Nav1.1, Nav1.3 and beta1 subunit were upregulated in the hippocampus of spontaneously epileptic rat. Brain Res Bull 75:179-187 (2008).
168. Rogawski MA Loscher W. The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions. Nat Med 10:685-692 (2004).
169. Rogawski MA, Loscher W. The neurobiology of antiepileptic drugs. Nat Rev Neurosci 5:553-564 (2004).
170. Ragsdale DS, McPhee JC, Scheuer T, CatterallWA. Common molecular determinants of local anesthetic, antiarrhythmic, and anticonvulsant block of voltage-gated Na+ channels. Proc Natl Acad Sci USA 93:9270-9275 (1996).
171. Smith MR, Smith RD, PlummerNW, Meisler MH, Goldin AL. Functional analysis of the mouse Scn8a sodium channel. J Neurosci 18:6093-6102 (1998).
172. Ophoff RA et al. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell 87:543-552 (1996).
173. Fusco MD et al. Haploinsufficiency of ATP1A2 encoding the Na+/K+ pump [alpha]2 subunit associated with familial hemiplegic migraine type 2. Nat Genet 33:192-196 (2003).
174. Martin D et al. Mutation in the neuronal voltage-gated sodium channel SCN1A in familial hemiplegic migraine. Lancet 366:371-377 (2005).
175. Kahlig KM et al. Divergent sodium channel defects in familial hemiplegic migraine. Proc Natl Acad Sci USA 105:9799-9804 (2008).
176. Escayg A et al. Mutations of SCN1A, encoding a neuronal sodium channel, in two families with GEFS+2. Nat Genet 24:343-345 (2000).
177. Lossin C et al. Epilepsy-associated dysfunction in the voltage-gated neuronal sodium channel SCN1A. J Neurosci 23:11289-11295 (2003).
178. Rhodes TH, Lossin C, Vanoye CG, Wang DW, George AL. Noninactivating voltagegated sodium channels in severe myoclonic epilepsy of infancy. Proc Natl Acad Sci USA 101:11147-11152 (2004).
179. Castro MJ et al. First mutation in the voltage-gated NaV1.1 subunit gene SCN1Awith cooccurring familial hemiplegic migraine and epilepsy. Cephalalgia 29:308-313 (2009).
180. Smith P et al. Sodium channel protein expression enhances the invasiveness of rat and human prostate cancer cells. FEBS Lett 423:19-24 (1998).
181. Laniado ME et al. Expression and functional analysis of voltage-activated Na+ channels in human prostate cancer cell lines and their contribution to invasion in vitro. Am J Pathol 150:1213-1221 (1997).
182. Diss JK et al. Expression of skeletal muscle-type voltage-gated Na+ channel in rat and human prostate cancer cell lines. FEBS Lett 427:5-10 (1998).
183. Diss JK, Archer SN, Hirano J, Fraser SP, Djamgoz MB. Expression profiles of voltagegated Na(+) channel alpha-subunit genes in rat and human prostate cancer cell lines. Prostate 48:165-178 (2001).
184. Bennett ES, Smith BA, Harper JM. Voltage-gated Na+ channels confer invasive properties on human prostate cancer cells. Pflugers Arch 447:908-914 (2004).
185. Diss JK et al. A potential novel marker for human prostate cancer: Voltage-gated sodium channel expression in vivo. Prostate Cancer Prostatic Dis 8:266-273 (2005).
186. Diss JK, Fraser SP, Djamgoz MB. Voltage-gated Na+ channels: Multiplicity of expression, plasticity, functional implications and pathophysiological aspects. Eur Biophys J 33:180-193 (2004).
187. Roger S, Besson P, Le Guennec JY. Involvement of a novel fast inward sodium current in the invasion capacity of a breast cancer cell line. Biochim Biophys Acta 1616:107-111 (2003).
188. Chioni A-M, Brackenbury WJ, Calhoun JD, Isom LL, Djamgoz MBA. A novel adhesion molecule in human breast cancer cells: Voltage-gated Na+ channel [beta]1 subunit. Int. J Biochem Cell Biol 41:1216-1227 (2009).
189. Ritchie JM, Rogart RB. Density of sodium channels in mammalian myelinated nerve fibers and nature of the axonal membrane under the myelin sheath. Proc Natl Acad Sci USA 74:211-215 (1977).
190. Smith KJ. Sodium channels and multiple sclerosis: Roles in symptom production, damage and therapy. Brain Pathol 17:230-242 (2007).
191. Mattson MP. Calcium and neurodegeneration. Aging Cell 6:337-350 (2007).
192. Gibbons SJ, Brorson JR, Bleakman D, Chard PS, Miller RJ. Calcium influx and neurodegenerationa. Ann NY Acad Sci 679:22-33 (1993).
193. Stys PK, Waxman SG, Ransom BR. Ionic mechanisms of anoxic injury in mammalian CNS white matter: Role of Na+ channels and Na(+)-Ca2+ exchanger. J Neurosci 12:430-439 (1992).
194. Lassmann H. Hypoxia-like tissue injury as a component of multiple sclerosis lesions. J Neurol Sci 206:187-191 (2003).
195. Ferguson B, Matyszak MK, Esiri MM, Perry VH. Axonal damage in acute multiple sclerosis lesions. Brain 120 (Pt 3):393-399 (1997).
196. Smith KJ, Lassmann H. The role of nitric oxide in multiple sclerosis. Lancet Neurol 1:232-241 (2002).
197. Brown GC, Borutaite V. Nitric oxide inhibition of mitochondrial respiration and its role in cell death. Free Radic Biol Med 33:1440-1450 (2002).
198. Garthwaite G, Goodwin DA, Batchelor AM, Leeming K, Garthwaite J. Nitric oxide toxicity in CNS white matter: An in vitro study using rat optic nerve. Neuroscience 109:145-155 (2002).
199. Kapoor R, Davies M, Blaker PA, Hall SM, Smith KJ. Blockers of sodium and calcium entry protect axons from nitric oxide-mediated degeneration. Ann Neurol 53:174-180 (2003).
200. Stys PK, Ransom BR, Waxman SG. Tertiary and quaternary local anesthetics protect CNS white matter from anoxic injury at concentrations that do not block excitability. J Neurophysiol 67:236-240 (1992).
201. Stys PK, Lesiuk H. Correlation between electrophysiological effects of mexiletine and ischemic protection in central nervous system white matter. Neuroscience 71:27-36 (1996).
202. Fern R, Ransom BR, Stys PK, Waxman SG. Pharmacological protection of CNS white matter during anoxia: Actions of phenytoin, carbamazepine and diazepam. J Pharmacol Exp Ther 266:1549-1555 (1993).
203. Lo AC, Saab CY, Black JA, Waxman SG. Phenytoin protects spinal cord axons and preserves axonal conduction and neurological function in a model of neuroinflammation in vivo. J Neurophysiol 90:3566-3571 (2003).
204. Bechtold DA, Kapoor R, Smith KJ. Axonal protection using flecainide in experimental autoimmune encephalomyelitis. Ann Neurol 55:607-616 (2004).
205. Bechtold DA et al. Axonal protection achieved in a model of multiple sclerosis using lamotrigine. J Neurol 253:1542-1551 (2006).
206. Gallin EK. Ion channels in leukocytes. Physiol Rev 71:775-811 (1991).
207. Roselli F, Livrea P, Jirillo E. Voltage-gated sodium channel blockers as immunomodulators. Recent Pat CNS Drug Discov 1:83-91 (2006).
208. Black JA, Liu S, Waxman SG. Sodium channel activity modulates multiple functions in microglia. Glia 57:1072-1081 (2009).
209. Craner MJ et al. Sodium channels contribute to microglia/macrophage activation and function in EAE and MS. Glia 49:220-229 (2005).
210. Black JA, Liu S, Carrithers M, Carrithers LM, Waxman SG. Exacerbation of experimental autoimmune encephalomyelitis after withdrawal of phenytoin and carbamazepine. Ann Neurol 62:21-33 (2007).
211. Catterall WA. Neurotoxins that act on voltage-sensitive sodium channels in excitable membranes. Annu Rev Pharmacol Toxicol 20:15-43 (1980).
212. Catterall WA, Risk M. Toxin T4(6) from Ptychodiscus brevis (formerly Gymnodinium breve) enhances activation of voltage-sensitive sodium channels by veratridine. Mol Pharmacol 19:345-348 (1981).
213. Poli M, Mende T, Baden D. Brevetoxins, unique activators of voltage-sensitive sodium channels, bind to specific sites in rat brain synaptosomes. Mol Pharmacol 30:129-135 (1986).
214. Fainzilber M, Kofman O, Zlotkin E, Gordon D. A new neurotoxin receptor site on sodium channels is identified by a conotoxin that affects sodium channel inactivation in molluscs and acts as an antagonist in rat brain. J Biol Chem269:2574-2580 (1994).
215. Catterall WA, Beneski DA. Interaction of polypeptide neurotoxins with a receptor site associated with voltage-sensitive sodium channels. J Supramol Struct 14:295-303 (1980).
216. Cestele S, Catterall WA. Molecular mechanisms of neurotoxin action on voltage-gated sodium channels. Biochimie 82:883-892 (2000).
217. Hille B. The receptor for tetrodotoxin and saxitoxin. A structural hypothesis. Biophys J 15:615-619 (1975).
218. Ohizumi Y, Nakamura H, Kobayashi J, Catterall WA. Specific inhibition of [3H] saxitoxin binding to skeletal muscle sodium channels by geographutoxin II, a polypeptide channel blocker. J Biol Chem 261:6149-6152 (1986).
219. Yanagawa Y, Abe T, Satake M. Blockade of [3H]lysine-tetrodotoxin binding to sodium channel proteins by conotoxin GIII. Neurosci Lett 64:7-12 (1986).
220. Dudley SC, Jr, Todt H, Lipkind G, Fozzard HA. A mu-conotoxin-insensitive Na+ channel mutant: Possible localization of a binding site at the outer vestibule. Biophys J 69:1657-1665 (1995).
221. Sato K et al. Active site of mu-conotoxin GIIIA, a peptide blocker of muscle sodium channels. J Biol Chem 266:16989-16991 (1991).
222. Catterall WA. Membrane potential-dependent binding of scorpion toxin to the action potential Na+ ionophore. Studies with a toxin derivative prepared by lactoperoxidasecatalyzed iodination. J Biol Chem 252:8660-8668 (1977).
223. Catterall WA. Activation of the action potential Na+ ionophore by neurotoxins. An allosteric model. J Biol Chem 252:8669-8676 (1977).
224. Kimura T et al. On site of action of grayanotoxin in domain 4 segment 6 of rat skeletal muscle sodium channel. FEBS Lett 465:18-22 (2000).
225. Linford NJ, Cantrell AR, Qu Y, Scheuer T, Catterall WA. Interaction of batrachotoxin with the local anesthetic receptor site in transmembrane segment IVS6 of the voltagegated sodium channel. Proc Natl Acad Sci USA 95:13947-13952 (1998).
226. Khodorov BI. Batrachotoxin as a tool to study voltage-sensitive sodium channels of excitable membranes. Prog Biophys Mol Biol 45:57-148 (1985).
227. Sutro JB. Kinetics of veratridine action on Na channels of skeletal muscle. J Gen Physiol 87:1-24 (1986).
228. Trainer VL, Brown GB, Catterall WA. Site of covalent labeling by a photoreactive batrachotoxin derivative near transmembrane segment IS6 of the sodium channel alpha subunit. J Biol Chem 271:11261-11267 (1996).
229. Wang S-Y, Mitchell J, Tikhonov DB, Zhorov BS,Wang GK. How batrachotoxin modifies the sodium channel permeation pathway: Computer modeling and site-directed mutagenesis. Mol Pharmacol 69:788-795 (2006).
230. Lombet A, Bidard JN, Lazdunski M. Ciguatoxin and brevetoxins share a common receptor site on the neuronal voltage-dependent Na+ channel. FEBS Lett 219:355-359 (1987).
231. Benoit E, Legrand AM, Dubois JM. Effects of ciguatoxin on current and voltage clamped frog myelinated nerve fibre. Toxicon 24:357-364 (1986).
232. Huang JM, Wu CH, Baden DG. Depolarizing action of a red-tide dinoflagellate brevetoxin on axonal membranes. J Pharmacol Exp Ther 229:615-621 (1984).
233. Trainer VL, Baden DG, Catterall WA. Identification of peptide components of the brevetoxin receptor site of rat brain sodium channels. J Biol Chem 269:19904-19909 (1994).
234. Tejedor FJ, Catterall WA. Site of covalent attachment of alpha-scorpion toxin derivatives in domain I of the sodium channel alpha subunit. Proc Natl Acad Sci USA 85:8742-8746 (1988).
235. Cestele S et al. Voltage sensor-trapping: Enhanced activation of sodium channels by beta-scorpion toxin bound to the S3-S4 loop in domain II. Neuron 21:919-931 (1998).
236. Bergman C, Dubois JM, Rojas E, Rathmayer W. Decreased rate of sodium conductance inactivation in the node of Ranvier induced by a polypeptide toxin from sea anemone. Biochim Biophys Acta 455:173-184 (1976).
237. Catterall WA. Binding of scorpion toxin to receptor sites associated with sodium channels in frog muscle. Correlation of voltage-dependent binding with activation. J Gen Physiol 74:375-391 (1979).
238. Nicholson GM, Walsh R, Little MJ, Tyler MI. Characterisation of the effects of robustoxin, the lethal neurotoxin from the Sydney funnel-web spider Atrax robustus, on sodium channel activation and inactivation. Pflugers Arch 436:117-126 (1998).
239. Nicholson GM, Willow M, Howden ME, Narahashi T. Modification of sodium channel gating and kinetics by versutoxin from the Australian funnel-web spider Hadronyche versuta. Pflugers Arch 428:400-409 (1994).
240. Pauron D, Barhanin J, Lazdunski M. The voltage-dependent Na+ channel of insect nervous system identified by receptor sites for tetrodotoxin, and scorpion and sea anemone toxins. Biochem Biophys Res Commun 131:1226-1233 (1985).
241. Rogers JC, Qu Y, Tanada TN, Scheuer T, Catterall WA. Molecular determinants of high affinity binding of alpha-scorpion toxin and sea anemone toxin in the S3-S4 extracellular loop in domain IV of the Na+ channel alpha subunit. J Biol Chem 271:15950-15962 (1996).
242. Benzinger GR, Kyle JW, Blumenthal KM, Hanck DA. A specific interaction between the cardiac sodium channel and site-3 toxin anthopleurin B. J Biol Chem 273:80-84 (1998).
243. Cahalan MD. Modification of sodium channel gating in frog myelinated nerve fibres by Centruroides sculpturatus scorpion venom. J Physiol 244:511-534 (1975).
244. Jonas P, VogelW, Arantes EC, Giglio JR. Toxin gamma of the scorpion Tityus serrulatus modifies both activation and inactivation of sodium permeability of nerve membrane. Pflugers Arch 407:92-99 (1986).
245. Wang GK, Strichartz GR. Purification and physiological characterization of neurotoxins from venoms of the scorpions centruroides sculpturatus and leiurus quinquestriatus. Mol Pharmacol 23:519-533 (1983).
246. Marcotte P, Chen LQ, Kallen RG, Chahine M. Effects of Tityus serrulatus scorpion toxin gamma on voltage-gated Na+ channels. Circ Res 80:363-369 (1997).
247. Leipold E, Hansel A, Borges A, Heinemann SH. Subtype specificity of scorpion betatoxin Tz1 interaction with voltage-gated sodium channels is determined by the pore loop of domain 3. Mol Pharmacol 70:340-347 (2006).
248. Hasson A, Fainzilber M, Gordon D, Zlotkin E, Spira ME. Alteration of sodium currents by new peptide toxins from the venom of a molluscivorous Conus snail. Eur J Neurosci 5:56-64 (1993).
249. Leipold E, Hansel A, Olivera BM., Terlau, H, Heinemann SH. Molecular interaction of delta-conotoxins with voltage-gated sodium channels. FEBS Lett 579:3881-3884 (2005).
250. Mantegazza M, Curia G, Biagini G, Ragsdale DS, Avoli M. Voltage-gated sodium channels as therapeutic targets in epilepsy and other neurological disorders. Lancet Neurol 9:413-424 (2010).
251. Tarnawa I, Bolcskei H, Kocsis P. Blockers of voltage-gated sodium channels for the treatment of central nervous systemdiseases.Recent PatCNSDrugDiscov 2:57-78 (2007).
252. Zuliani V, Patel MK, Fantini M, Rivara M. Recent advances in the medicinal chemistry of sodium channel blockers and their therapeutic potential. Curr Top Med Chem 9:396-415 (2009).
253. McElroy SL et al. Role of antiepileptic drugs in the management of eating disorders. CNS Drugs 23:139-156 (2009).
254. LenkeyNet al.Classification of drugs based on properties of sodiumchannel inhibition: A comparative automated patch-clamp study. PLoS One 5(12):e15568 (2010).
255. Dekker LVet al. Analysis of human Nav1.8 expressed in SH-SY5Y neuroblastoma cells. Eur J Pharmacol 528:52-58 (2005).
256. Browne LE, Blaney FE, Yusaf SP, Clare JJ, Wray D. Structural determinants of drugs acting on the Nav1.8 channel. J Biol Chem 284:10523-10536 (2009).
257. Browne LE, Clare JJ, Wray D. Functional and pharmacological properties of human and rat NaV1.8 channels. Neuropharmacology 56:905-914 (2009).
258. Dib-Hajj S, Black JA, Cummins TR,Waxman SG. NaN/Nav1. 9: A sodium channel with unique properties. Trends Neurosci 25:253-259 (2002).
259. CatterallW. From ionic currents to molecular mechanisms: The structure and function of voltage-gated sodium channels. Neuron 26:13-25 (2000).
260. Cusdin FS et al. The sodium channel {beta}3-subunit induces multiphasic gating in NaV1.3 and affects fast inactivation via distinct intracellular regions. J Biol Chem 285:33404-33412.
261. Takahashi N et al. Expression of auxiliary beta subunits of sodium channels in primary afferent neurons and the effect of nerve injury. Neuroscience 121:441-450 (2003).
262. Becker S, Terlau H. Toxins from cone snails: Properties, applications and biotechnological production. Appl Microbiol Biotechnol 79:1-9 (2008).
263. Dunlop J, Bowlby M, Peri R, Vasilyev D, Arias R. High-throughput electrophysiology: An emerging paradigm for ion-channel screening and physiology. Nat Rev Drug Discov 7:358-368 (2008).
264. Xu J et al. Ion-channel assay technologies: Quo vadis? Drug Discov Today 6:1278-1287 (2001).
265. Castle N et al. Sodium channel inhibitor drug discovery using automated high throughput electrophysiology platforms. Comb Chem High Throughput Screen 12:107-122 (2009).
266. Fermini B. Recent advances in ion channel screening technologies. In Fermini B, Priest B. eds. Ion Channels. Springer, 2008, pp. 1-26.
267. Mathes C, Friis S, Finley M, Liu Y. QPatch: The missing link between HTS and ion channel drug discovery. Comb Chem High Throughput Screen 12:78-95 (2009).
268. Finkel A et al. Population patch clamp improves data consistency and success rates in the measurement of ionic currents. J Biomol Screen 11:488-496 (2006).
269. Mathes C. QPatch: The past, present and future of automated patch clamp. Expert Opin Ther Targets 10:319-327 (2006).
270. Jones KA, Garbati N, Zhang H, Large CH. Automated patch clamping using the QPatch. Methods Mol Biol 565:209-223 (2009).
271. Ghetti A, Guia A, Xu J. Automated voltage-clamp technique. Methods Mol Biol 403:59- 69 (2007).
272. Guo L, Guthrie H. Automated electrophysiology in the preclinical evaluation of drugs for potential QT prolongation. J Pharmacol Toxicol Methods 52:123-135 (2005).
273. Dale TJ, Townsend C, Hollands EC, Trezise DJ. Population patch clamp electrophysiology: A breakthrough technology for ion channel screening. Mol Biosyst 3:714-722 (2007).
274. Penniman JR, Kim DC, Salata JJ, Imredy JP. Assessing use-dependent inhibition of the cardiac Na(+/-) current (I(Na)) in the PatchXpress automated patch clamp. J Pharmacol Toxicol Methods 62:107-118.
275. Xu J et al. A benchmark study with sealchip planar patch-clamp technology. Assay Drug Dev Technol 1:675-684 (2003).
276. Balasubramanian B et al. Optimization of Ca(v)1.2 screening with an automated planar patch clamp platform. J Pharmacol Toxicol Methods 59:62-72 (2009).
277. Dubin AE et al. Identifying modulators of hERG channel activity using the PatchXpress planar patch clamp. J Biomol Screen 10:168-181 (2005).
278. Dunlop J et al. In vitro screening strategies for nicotinic receptor ligands. Biochem Pharmacol 74:1172-1181 (2007).
279. Mo ZL et al. Effect of compound plate composition on measurement of hERG current IC(50) using PatchXpress. J Pharmacol Toxicol Methods 60:39-44 (2009).
280. Trepakova ES et al. Application of PatchXpress planar patch clamp technology to the screening of new drug candidates for cardiac KCNQ1/KCNE1 (I Ks) activity. Assay Drug Dev Technol 5:617-627 (2007).
281. Friis S, Mathes C, Sunesen M, Bowlby MR, Dunlop J. Characterization of compounds on nicotinic acetylcholine receptor alpha7 channels using higher throughput electrophysiology. J Neurosci Methods 177:142-148 (2009).
282. Korsgaard MP, Strobaek D, Christophersen P. Automated planar electrode electrophysiology in drug discovery: Examples of the use of QPatch in basic characterization and high content screening on Na(v), K(Ca)2.3, and K(v)11.1 channels. Comb Chem High Throughput Screen 12:51-63 (2009).
283. Kutchinsky J et al. Characterization of potassium channel modulators with QPatch automated patch-clamp technology: System characteristics and performance. Assay Drug Dev Technol 1:685-693 (2003).
284. Fejtl M, Czubayko U, Hummer A, Krauter T, Lepple-Wienhues A. Flip-the-tip: Automated patch clamping based on glass electrodes. Methods Mol Biol 403:71-85 (2007).
285. Bruggemann A et al. High quality ion channel analysis on a chip with the NPC technology. Assay Drug Dev Technol 1:665-673 (2003).
286. Farre C et al. Port-a-patch and patchliner: High fidelity electrophysiology for secondary screening and safety pharmacology. Comb Chem High Throughput Screen 12:24-37 (2009).
287. Bridgland-Taylor MH et al. Optimisation and validation of a medium-throughput electrophysiology-based hERG assay using IonWorks HT. J Pharmacol Toxicol Methods 54:189-199 (2006).
288. Chambers C et al. Measuring intracellular calcium fluxes in high throughput mode. Comb Chem High Throughput Screen 6:355-362 (2003).
289. Clare JJ, Tate SN, Nobbs M, Romanos MA. Voltage-gated sodium channels as therapeutic targets. Drug Discov Today 5:506-520 (2000).
290. Trivedi S et al. Cellular HTS assays for pharmacological characterization of Na(V)1.7 modulators. Assay Drug Dev Technol 6:167-179 (2008).
291. Benjamin ER et al. State-dependent compound inhibition of Nav1.2 sodium channels using the FLIPR Vm dye: On-target and off-target effects of diverse pharmacological agents. J Biomol Screen 11:29-39 (2006).
292. Connick JH. A flexible technology platform to explore valuable drug targets. Biochem Soc Trans 30:786-788 (2002).
293. Huang CJ et al. Characterization of voltage-gated sodium-channel blockers by electrical stimulation and fluorescence detection of membrane potential. Nat Biotechnol 24:439- 446 (2006).
294. Bhattacharya A, Wang Q, Wu N, Wickenden AD. Assay dependent activity of the sodium channel gating modifier protoxin-I: Implications for sodium channel drug discovery. FASEB J 23 (Suppl.):998.31 (2009).
295. Manger RL et al. Detection of sodium channel toxins: Directed cytotoxicity assays of purified ciguatoxins, brevetoxins, saxitoxins, and seafood extracts. J Assoc Official Anal Chem Int 78:521-527 (1995).
296. Gallacher S, Birkbeck TH. A tissue culture assay for direct detection of sodium channel blocking toxins in bacterial culture supernates. FEMS Microbiol Lett 71:101-107 (1992).
297. FrantzS.The troublewithmaking combination drugs. Nat Rev Drug Discov 5:881-882 (2006).
298. Escoubas P, King GF. Venomics as a drug discovery platform. Expert Rev. Proteom 6:221-224 (2009).
299. DiMasi JA, Paquette C. The economics of follow-on drug research and development: Trends in entry rates and the timing of development. Pharmacoeconomics 22:1-14 (2004).
300. Newman DJ, Cragg GM. Natural products as sources of new drugs over the last 25 years. J Nat Prod 70:461-477 (2007).
301. Lewis RJ, Garcia ML. Therapeutic potential of venom peptides. Nat Rev Drug Discov 2:790-802 (2003).
302. Dutertre S, Lewis RJ. Use of venom peptides to probe lon channel structure and function. J. Biol. Chem. 285:13315-13320 (2010).
303. Billen B, Bosmans F, Tytgat J. Animal peptides targeting voltage-activated sodium channels. Curr Pharm Design 14:2492-2502 (2008).
304. Matsumura M, Signor G, Matthews BW. Substantial increase of protein stability by multiple disulphide bonds. Nature 342:291-293 (1989).
305. Olivera BM. Conus peptides: Biodiversity-based discovery and exogenomics. J Biol Chem 281:31173-31177 (2006).
306. Possani LD, Becerril B, Delepierre M, Tytgat J. Scorpion toxins specific for Na+-channels. Eur J Biochem 264:287-300 (1999).
307. Rodriguez de la Vega RC, Possani LD. Overview of scorpion toxins specific for Na+ channels and related peptides: Biodiversity, structure-function relationships and evolution. Toxicon 46:831-844 (2005).
308. Rodríguez de la Vega RC, Schwartz EF, Possani LD. Mining on scorpion venom biodiversity. Toxicon 56:1155-1161 (2010).
309. Bosmans F, Tytgat J. Voltage-gated sodium channel modulation by scorpion alphatoxins. Toxicon 49:142-158 (2007).
310. Platnick NI. The world spider catalog, version 12.5. American Museum of Natural History, 2012, online at http://research.amnh.org/iz/spiders/catalog. DOI: 10.5531/db.iz.0001.
311. Escoubas P, Sollod B, King GF. Venomlandscapes:Mining the complexity of spider venoms via a combined cDNA and mass spectrometric approach. Toxicon 47:650-663 (2006).
312. Pimenta AM et al. Electrospray ionization quadrupole time-of-flight and matrixassisted laser desorption/ionization tandem time-of-flight mass spectrometric analyses to solvemicro-heterogeneity in post-translationally modified peptides from Phoneutria nigriventer (Aranea, Ctenidae) venom. Rapid Commun Mass Spectrom 19:31-37 (2005).
313. Norton RS, Pallaghy PK. The cystine knot structure of ion channel toxins and related polypeptides. Toxicon 36:1573-1583 (1998).
314. Peng K, Shu Q, Liu Z, Liang S. Function and solution structure of huwentoxin-IV, a potent neuronal tetrodotoxin (TTX)-sensitive sodium channel antagonist from Chinese bird spider Selenocosmia huwena. J Biol Chem 277:47564-47571 (2002).
315. Xiao Y, Liang S. Inhibition of neuronal tetrodotoxin-sensitive Na+ channels by two spider toxins: Hainantoxin-III and hainantoxin-IV. Eur J Pharmacol 477:1-7 (2003).
316. Xiao YC, Liang SP. Purification and characterization of Hainantoxin-V, a tetrodotoxinsensitive sodium channel inhibitor from the venom of the spider Selenocosmia hainana. Toxicon 41:643-650 (2003).
317. Xiao Y, Li J, Deng M, Dai C, Liang S. Characterization of the excitatory mechanism induced by Jingzhaotoxin-I inhibiting sodium channel inactivation. Toxicon 50:507-517 (2007).
318. Xiao Yet al. Jingzhaotoxin-I, a novel spider neurotoxin preferentially inhibiting cardiac sodium channel inactivation. J Biol Chem 280:12069-12076 (2005).
319. Nicholson GM, Little MJ, Birinyi-Strachan LC. Structure and function of [delta]- atracotoxins: Lethal neurotoxins targeting the voltage-gated sodium channel. Toxicon 43:587-599 (2004).
320. Little MJ et al. [delta]-Atracotoxins from Australian funnel-web spiders compete with scorpion [alpha]-toxin binding on both rat brain and insect sodium channels. FEBS Lett 439:246-252 (1998).
321. Zeng X-Z, Xiao Q-B, Liang S-P. Purification and characterization of raventoxin-I and raventoxin-III, two neurotoxic peptides from the venom of the spider Macrothele raveni. Toxicon 41:651-656 (2003).
322. Corzo G et al. Distinct primary structures of the major peptide toxins from the venom of the spider Macrothele gigas that bind to sites 3 and 4 in the sodium channel. FEBS Lett 547:43-50 (2003).
323. Xiao Yet al. Jingzhaotoxin-III, a novel spider toxin inhibiting activation of voltage-gated sodium channel in rat cardiac myocytes. J Biol Chem 279:26220-26226 (2004).
324. Olivera BM. E.E. Just Lecture, 1996. Conus venom peptides, receptor and ion channel targets, and drug design: 50 million years of neuropharmacology. Mol Biol Cell 8:2101- 2109 (1997).
325. Terlau H et al. Strategy for rapid immobilization of prey by a fish-hunting marine snail. Nature 381:148-151 (1996).
326. Olivera BM Conus venom peptides: Reflections from the biology of clades and species. Annu Rev Ecol Systematics 33:25-47 (2002).
327. Terlau H, Olivera BM. Conus venoms: A rich source of novel ion channel-targeted peptides. Physiol Rev 84:41-68 (2004).
328. Olivera BM, Teichert RW. Diversity of the neurotoxic Conus peptides: A model for concerted pharmacological discovery. Mol Interv 7:251-260 (2007).
329. Olivera BM et al. Diversity of Conus neuropeptides. Science 249:257-263 (1990).
330. Davis J, Jones A, Lewis RJ. Remarkable inter- and intra-species complexity of conotoxins revealed by LC/MS. Peptides 30:1222-1227 (2009).
331. Lewis RJ et al. Isolation and structure-activity of m-conotoxin TIIIA, a potent inhibitor of tetrodotoxin-sensitive voltage-gated sodium channels. Mol Pharmacol 71:676-685 (2007).
332. Zhang MM et al. Structural and functional diversities among mu-conotoxins targeting TTX-resistant sodium channels. Biochemistry 45:3723-3732 (2006).
333. Ekberg J, Craik DJ, Adams DJ. Conotoxin modulation of voltage-gated sodium channels. Int J Biochem Cell Biol 40:2363-2368 (2008).
334. Terlau H, Stocker M, Shon KJ, McIntosh JM, Olivera BM. MicroO-conotoxin MrVIA inhibits mammalian sodium channels, but not through site I. J Neurophysiol 76:1423-1429 (1996).
335. Zorn S et al. The [mu]O-conotoxin MrVIA inhibits voltage-gated sodium channels by associating with domain-3. FEBS Lett 580:1360-1364 (2006).
336. Ekberg J et al. muO-conotoxin MrVIB selectively blocks Nav1.8 sensory neuron specific sodium channels and chronic pain behavior without motor deficits. Proc Natl Acad Sci USA 103:17030-17035 (2006).
337. Bulaj G et al. Synthetic muO-conotoxin MrVIB blocks TTX-resistant sodium channel NaV1.8 and has a long-lasting analgesic activity. Biochemistry 45:7404-7414 (2006).
338. Bulaj G et al. Delta-conotoxin structure/function through a cladistic analysis. Biochemistry 40:13201-13208 (2001).
339. Jimenez EC et al. Novel excitatory Conus peptides define a new conotoxin superfamily. J Neurochem 85:610-621 (2003).
340. Wang L et al. Identification of a novel M-superfamily conotoxin with the ability to enhance tetrodotoxin sensitive sodium currents. Arch Toxicol 83:925-932 (2009).
341. Liu J et al. Isolation and characterization of aT-superfamily conotoxin fromConus litteratus with targeting tetrodotoxin-sensitive sodium channels. Peptides 28:2313-2319 (2007).
342. Aguilar MB et al. A biologically active hydrophobic T-1-conotoxin from the venom of Conus spurius. Peptides 27:500-505 (2006).
343. Olivera BM, Teichert RW. Diversity of the neurotoxic conus peptides: A model for concerted pharmacological discovery. Mol Interv 7:251-260 (2007).
344. Sollod BL et al.Were arachnids the first to use combinatorial peptide libraries? Peptides 26:131-139 (2005).
345. Escoubas P, Rash L. Tarantulas: Eight-legged pharmacists and combinatorial chemists. Toxicon 43:555-574 (2004).
346. Gambardella A, Marini C. Clinical spectrum of SCN1A mutations. Epilepsia 50 (Suppl 5):20-23 (2009).
347. Ahmed CM et al. Primary structure, chromosomal localization, and functional expression of a voltage-gated sodium channel from human brain. Proc Natl Acad Sci USA 89:8220-8224 (1992).
348. Hirn C, Shapovalov G, Petermann O, Roulet E, Ruegg UT. Nav1.4 deregulation in dystrophic skeletal muscle leads to Na+overload and enhanced cell death. J Gen Physiol 132:199-208 (2008).
349. Matthews E et al. Voltage sensor charge loss accounts for most cases of hypokalemic periodic paralysis. Neurology 72:1544-1547 (2009).
350. Osorio N et al. Persistent Nav1.6 current at axon initial segments tunes spike timing of cerebellar granule cells. J Physiol 588(Pt 4): 651-670 (2010).
351. Thakor DK et al. Increased peripheral nerve excitability and local NaV1.8 mRNA upregulation in painful neuropathy. Mol Pain 5:14 (2009).
352. Lang DG, Wang CM, Cooper BR. Lamotrigine, phenytoin and carbamazepine interactions on the sodium current present in N4TG1 mouse neuroblastoma cells. J Pharmacol Exp Ther 266:829-835 (1993).
353. Taverna S, Sancini G, Mantegazza M, Franceschetti S,Avanzini G. Inhibition of transient and persistent Na+ current fractions by the new anticonvulsant topiramate. J Pharmacol Exp Ther 288:960-968 (1999).
354. Errington AC, Stohr T, Heers C, Lees G. The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Mol Pharmacol 73:157-169 (2008).
355. Song J-H, Ham S-S, Shin Y-K, Lee C-S. Amitriptyline modulation of Na+ channels in rat dorsal root ganglion neurons. Eur J Pharmacol 401:297-305 (2000).
356. Yamane H, de Groat WC, Sculptoreanu A. Effects of ralfinamide, a Na+ channel blocker, on firing properties of nociceptive dorsal root ganglion neurons of adult rats. Exp Neurol 208:63-72 (2007).
357. Jarvis MF et al. A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat. Proc Natl Acad Sci USA 104:8520-8525 (2007).
358. Tanelian DL, Brose WG. Neuropathic pain can be relieved by drugs that are usedependent sodium channel blockers: Lidocaine, carbamazepine, and mexiletine. Anesthesiology 74:949-951 (1991).
359. Rang HP, Dale MM, Ritter JM, Flower R. Rang and Dale's Pharmacology, Churchill Livingstone, Edinburgh, 2007.
360. Watanabe H et al. Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. Nat Med 15:380-383 (2009).
361. Kahlig KM, Lepist I, Leung K, Rajamani S, George AL. Ranolazine selectively blocks persistent current evoked by epilepsy-associated NaV1.1 mutations. Br J Pharmacol 161:1414-1426 (2010).
362. Gissen AJ, Covino BG, Gregus J. Differential sensitivities of mammalian nerve fibers to local anesthetic agents. Anesthesiology 53:467-474 (1980).
363. French RJ,Worley, JF 3rd Krueger BK. Voltage-dependent block by saxitoxin of sodium channels incorporated into planar lipid bilayers. Biophysical J 45:301-310 (1984).
364. Narahashi, T. Tetrodotoxin: A brief history. Proc Jpn Acad Ser B Phys Biol Sci 84:147- 154 (2008).
365. Strachan LC, Lewis RJ, Nicholson GM. Differential actions of pacific ciguatoxin-1 on sodium channel subtypes in mammalian sensory neurons. J Pharmacol Exp Ther 288:379-388 (1999).
366. Murrell R, Gibson J. Brevetoxins 2 3, 6, and 9 show variability in potency and cause significant induction of DNA damage and apoptosis in Jurkat E6-1 cells. Arch Toxicology 83:1009-1019 (2009).
367. Wang GK,Wang SY. Veratridine block of rat skeletal muscle Nav1.4 sodium channels in the inner vestibule. J Physiol 548:667-675 (2003).